G1 Therapeutics

G1 Therapeutics is a company listed under the stock ticker GTHX (US).

View the org chart displaying its 17 main executives

Most searched biographies at G1 Therapeutics

• Jack Bailey, Chief Executive Officer
• Garry Nicholson, Chairman of the Board
• Glenn Muir, Director

Create your alert
to follow the executive moves at G1 Therapeutics.

G1 Therapeutics has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by G1 Therapeutics

• G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights - G1 Therapeutics, Inc.
• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - G1 Therapeutics, Inc.
• G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference - G1 Therapeutics, Inc.
• G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors - G1 Therapeutics, Inc.
• G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022 - G1 Therapeutics, Inc.
• COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - G1 Therapeutics, Inc.
• G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors - G1 Therapeutics, Inc.
• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - G1 Therapeutics, Inc.
• G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer - G1 Therapeutics, Inc.
• Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy - G1 Therapeutics, Inc.
• View more press releases Close

Social media about G1 Therapeutics

• G1 Therapeutics on Wikipedia, Google News & Yahoo Finance
• G1 Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Jack Bailey

Call G1 Therapeutics at +1 919...

View the org chart

Register to receive your alert

Report an error